Infective Endocarditis Trial Backs Less Intense Antibiotic Approach

A recent clinical trial comparing shorter antibiotic treatments to standard care for infective endocarditis, a serious heart infection, has found that a tailored approach can be equally effective while potentially reducing side effects and costs. Conducted by researchers from the University of Copenhagen in Denmark, the POET II trial involved 508 patients with infective endocarditis caused by Staphylococcus aureus, Enterococcus faecalis, or Streptococcus species.

After achieving clinical stability, typically after 2-4 weeks of antibiotics, patients were randomized to either continue treatment for an additional 4-6 weeks or discontinue the medication, a strategy known as a tailored approach. The study found that patients receiving the tailored approach were hospitalized for 15 fewer days compared to those in the standard treatment group, with no increased risk of serious complications or death within six months.

However, the standard treatment group had a lower risk of relapse during the same period. The researchers suggest that defining a patient's stability point is crucial in tailoring endocarditis treatment, which could lead to personalized care and potentially improved outcomes. While the results are promising, the study's authors acknowledge that the findings may not apply to infections caused by less common pathogens, as the trial only included three major types of infective endocarditis pathogens.